Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2005-08-31
2009-02-10
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S192100, C514S002600
Reexamination Certificate
active
07488478
ABSTRACT:
A method for treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function using a cadherin-11 modulating agent is provided. Also provided are screening assays for identifying pharmaceutical lead compounds capable of modulating cellular functions of cadherin-11 such as cell proliferation, apoptosis, factor secretion, and binding of cadherin-11 to cadherin-11 counter-receptor inhibiting binding of cadherin-11 to its counter-receptor either in the context of a cell or in soluble form.
REFERENCES:
patent: 5597725 (1997-01-01), Suzuki
patent: 5639634 (1997-06-01), Suzuki
patent: 5646250 (1997-07-01), Suzuki
patent: 5708143 (1998-01-01), Suzuki
patent: 5798224 (1998-08-01), Suzuki
patent: 5886026 (1999-03-01), Hunter
patent: 6086877 (2000-07-01), Nishioka et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6433149 (2002-08-01), Blaschuk et al.
patent: 6472367 (2002-10-01), Blaschuk et al.
patent: 6787136 (2004-09-01), Brenner et al.
patent: 6964768 (2005-11-01), Brenner et al.
patent: WO 93/21302 (1993-10-01), None
patent: WO 98/02452 (1998-01-01), None
patent: WO 98/25946 (1998-06-01), None
patent: WO 98/49560 (1998-11-01), None
patent: WO 98/49560 (1998-11-01), None
patent: WO 99/35166 (1999-07-01), None
Kuntz. Structure-based strategies for drug design and discovery. Science. 1992 257(5073):1078-1082.
Miller et al Ligand binding to proteins: the binding landscape model. Protein Sci. Oct. 2007;6(10):2166-79.
Branch AD. A good antisense molecule is hard to find. Trends Biochem Sci. Feb. 1998;23(2):45-50.
Van Noort JM, Amor S. Cell biology of autoimmune diseases. Int Rev Cytol. 1998;178:127-206.
Mountain A. Gene therapy: the first decade. Trends Biotechnol. Mar. 2000;18(3):119-28.
Kahan BD. Immunosuppressive therapy. Curr Opin Immunol. 4(5):553-560, 1992.
Ngo J.T, Marks J., Karplus M., Computational complexity, protein structure prediction, and the Levinthal paradox in The Protein Folding Problem, ch.14, pp. 491-494, Birkhauser, 1994.
Hoffmann et al. Cloning and expression analysis of a novel mesodermally expressed cadherin. Dev Biol. May 1995;169(1):337 46.
Valencia et al., Identification of cadherin-11 in type B synoviocytes derived from rheumatoid arthritis patients. Arthritis and Rheumatism. Sep. 1998;41(9):s190.
Branch et al., A good antisense molecule is hard to find. Trends Biochem Sci. Feb 1998;23(2):45-50.
Cepek et al., Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol. Apr. 15, 1993;150(8 Pt 1):3459-70.
Falcini et al., Cadherins expression in autoimmune diseases. Arthritis Rheum. 1997; Suppl 40: s283.
Hoffmann et al., Cloning and expression analysis of a novel mesodermally expressed cadherin. Dev Biol. May 1995;169(1):337-46.
Jorgensen et al., In vivo migration of radiolabelled lymphocytes in rheumatoid synovial tissue engrafted in SCID mice: implication of beta 2 and beta 7-integrin. J Rheumatol. Jan. 1996;23(1):32-5.
Kahan et al., Immunosuppressive therapy. Curr Opin Immunol. Oct. 1992;4(5):553-60.
Kiener et al.; Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol. May 2006;168(5):1486-99. Abstract Only.
MacCalman et al., Regulated expression of cadherin-11 in human epithelial cells: a role for cadherin-11 in trophoblast-endometrium interactions? Dev Dyn. Jun. 1996;206(2):201-11.
Mountain, Gene therapy: the first decade. Trends Biotechnol. Mar. 2000;18(3):119-28.
Ngo et al., Computational complexity, protein structure prediction, and the Levinthal paradox in the protein folding problem. Birkhauser. 1994; Ch14:491-4.
Tanihara et al., Cloning of five human cadherins clarifies characteristic features of cadherin extracellular domain and provides further evidence for two structurally different types of cadherin. Cell Adhes Commun. Apr. 1994;2(1):15-26.
Trollmo et al., Expression of the mucosal lymphocyte integrin alpha E beta 7 and its ligand E-cadherin in the synovium of patients with rheumatoid arthritis. Scand J Immunol. Sep. 1996;44(3):293-8.
Valencia et al., Cadherin-11 mediates adhesion of type B synoviocytes in rheumatoid arthritis. Arthritis & Rheumatism. Sep. 1999;42(9): S89. Abstract 111.
Van Noort et al., Cell biology of autoimmune diseases. Int Rev Cytol. 1998;178:127-206.
Breedveld, F.C, “Early Rheumatoid Arthritis. Future Treatment”,Baillière's Clinical Rheumatology, vol. 11, 1997, pp. 83-96.
Chitaev et al., “Molecular Organization of the Desmoglein-Plakoglobin Complex”,J Cell Sci., Jul. 30, 1998;111 (Pt 14):1941-9.
Finck et al., Treatment of Murine Lupus with CTLA41g, 1:Science, Aug. 26, 1994;265(5176):1225-7.
Gorczynski et al., “An Immunoadhesin Incorporating the Molecule OX-2 Is a Potent Immunosuppressant That Prolongs Allo- and Xenograft Survival”,The American Association of Immunologists, 1999, pp. 1654-1660.
Gorczynski et al., “CD200 Immunoadhesin Supresses Collagen-Induced Arthritis in Mice”,Clinical Immunology, vol. 101, No. 3, December, pp. 328-334, 2001.
Noë et al., “Inhibition of adhesion and induction of epithelial cell invasion by HAV-containing E-cadherin-specific peptides”,J Cell Sci. Jan. 1999;112 ( Pt 1):127-35.
Okazaki et al., “Molecular Cloning and Characterization of OB-cadherin , a New Member of Cadherin Family Expressed in Osteoblasts”,The Journal of Biological Chemistry, vol. 269, No. 16, Apr. 22, 1994, pp. 12092-12098.
Steurer et al., “Ex Vivo Coating of Islet Cell Allografts with Murine CTLA4/Fc Promotes Graft Tolerance”,The American Association of Immunologists, 1995, pp. 1165-1174.
Suzuki et al., “Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue”,Cell Regulation, vol. 2, 261-270, Apr. 1991, pp. 261-270.
Wilby et al., “N-Cadherin inhibits Schwann cell migration on astrocytes”,Mol Cell Neurosci., Jul. 1999;14(1):66-84.
Office Action mailed Apr. 26, 2002 for U.S. Appl. No. 09/654,328.
Office Action mailed Jan. 14, 2003, for U.S. Appl. No. 09/654,328.
Office Action mailed Dec. 15, 2003, for U.S. Appl. No. 09/654,328.
Office Action mailed Jun. 30, 2004, for U.S. Appl. No. 10/457,257.
Office Action mailed Feb. 9, 2005, for U.S. Appl. No. 10/457,257.
Office Communications mailed Nov. 3, 2008 for U.S. Appl. No. 11/986,471 (B0801.70287US02).
Brenner Michael B.
Valencia Xavier
Haddad Maher M
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and compositions for treatment of inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4067208